Tag: PsyBio Therapeutics - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

Post published:December 8, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

Post published:December 1, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

Post published:October 11, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Post published:September 19, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

Post published:September 7, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Post published:August 30, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Post published:August 12, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications

PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications

Post published:August 9, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders

Post published:June 29, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

Post published:June 2, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.